For the three months ended September 30, 2022, we had a net
income of $736,637, which primarily consists of change in fair
value of warrant liabilities of $642,000, offset by operating
expenses of $249,307, accrual of Delaware franchise taxes of
$50,000, dividend income of $193,267, unrealized gain on marketable
securities of $272,353 and income tax expense of $71,676.
For the nine months ended September 30, 2022, we had a net
income of $1,690,424, which primarily consists of change in fair
value of warrant liabilities of $1,997,334, offset by operating
expenses of $696,460, and accrual of Delaware franchise taxes of
$150,000, interest income of $124,277 and dividend income of
$216,596, unrealized gain on marketable securities held in Trust
account of $272,353 and income tax expense of $73,676.
Liquidity and Capital Resources
The registration statement for the Company’s Initial Public
Offering was declared effective on October 14, 2021. On
October 19, 2021, the Company consummated the Initial Public
Offering of 10,000,000 units (“Units”), each of which consisted of
one warrant and one share of Common Stock (the “Public Shares”) at
$10.00 per Unit, generating gross proceeds of $100,000,000 (as
discussed in Note 3).
Simultaneously with the closing of the Initial Public Offering, the
Company consummated the sale of 7,133,333 Private Placement
Warrants at a price of $0.75 per Private Placement Warrant in a
private placement to the Sponsor, for gross proceeds of $5,350,000
which is described in Note 4.
Offering costs for the Initial Public Offering amounted to
$6,101,730, consisting of $2,000,000 of underwriting fees,
$3,500,000 of deferred underwriting fees payable (which are held in
the Trust Account) and $601,730 of other costs. As described in
Note 6, the $3,500,000 of deferred underwriting fee payable is
contingent upon the consummation of a Business Combination by
January 19, 2023 (which is 15 months from the October 19,
2021 closing of our Initial Public Offering), or April 19,
2023 (which is 18 months from the October 19, 2021 closing of
our Initial Public Offering), subject to the terms of the
underwriting agreement. Following the closing of the Initial Public
Offering, $101,500,000 ($10.15 per Unit) from the net proceeds of
the sale of the Units in the Initial Public Offering and the
Private Placement Warrants was placed in the Trust Account.
For the nine months ended September 30, 2022, there was $447,115 of
cash used in operating activities, $107,883 cash provided by
investing activities and zero cash used in financing
activities.
At September 30, 2022, we had cash and marketable securities held
in the Trust Account of $102,007,218. We intend to use
substantially all of the funds held in the Trust Account, including
any amounts representing interest earned on the Trust Account (less
income taxes payable), to complete our Business Combination. To the
extent that our capital stock or debt is used, in whole or in part,
as consideration to complete our Business Combination, the
remaining proceeds held in the Trust Account will be used as
working capital to finance the operations of the target business or
businesses, make other acquisitions and pursue our growth
strategies.
At September 30, 2022, we had cash of $432,154 outside of the Trust
Account. We intend to use the funds held outside the Trust Account
primarily to identify and evaluate target businesses, perform
business due diligence on prospective target businesses, travel to
and from the offices, plants or similar locations of prospective
target businesses or their representatives or owners, review
corporate documents and material agreements of prospective target
businesses, and structure, negotiate and complete a Business
Combination.
In addition, in order to finance transaction costs in connection
with a Business Combination, the Sponsor or an affiliate of the
Sponsor, or certain of the Company’s officers and directors may,
but are not obligated to, loan the Company funds as may be required
(“Working Capital Loans”). If our Sponsor makes any working capital
loans, up to $1,500,000 of such loans may be converted into
warrants, at the price of $0.75 per warrant at the option of the
Sponsor. Such warrants would be identical to the Private Placement
Warrants, including as to exercise price, exercisability and
exercise period. If the Company completes a Business Combination,
the Company would repay the Working Capital Loans out of the
proceeds of the Trust Account released to the Company. Otherwise,
the Working Capital Loans would be repaid only out of funds held
outside the Trust Account. In the event that a Business Combination
does not close, the Company may use a portion of proceeds held
outside the Trust Account to repay the Working Capital Loans, but
no proceeds held in the Trust Account would be used to repay the
Working Capital Loans. Except for the foregoing, the terms of such
Working Capital Loans, if any, have not been determined and no
written agreements exist with respect to such loans. As of
September 30, 2022, the Company had no borrowings under the Working
Capital Loans.
19